GAAP EPS1
$2.95
2022 Performance Summary Infographic - Bristol-Myers Squibb
TOTAL NET SALES
$46.2B
Consistent with prior year or, an increase of 3% when excluding foreign exchange
7%
In-Line Brand
YoY% growth
87%
New Product Portfolio*
YoY% growth
Potential for risk-adjusted sales of $10-$13B revenues in 2025
Potential for $25B+ of non-risk adjusted revenues in 2030
Non-GAAP EPS1,2
$7.70
Significant Pipeline Advancement in 2022
18
approvals in the US, EU and Japan
| 9 |  |
approvals for Opdivo; Opdivo plusYervoy
5
positive registrational
topline readouts
$9.5B
invested in research
and development
Launched 3 First-In-Class Medicines
For metastatic melanoma
For obstructive hypertrophic cardiomyopathy
For moderate to severe plaque psoriasis
Strategically Positioned for Multiple Waves of Innovation
9
new products launched over
~3 years3
| 15+ |  |
additional indications
over ~3 years3
6
high potential mid-late
stage registrational assets
across therapeutic areas
| 50+ |  |
early-stage assets
in development
Balanced Approach to Capital Allocation
$13.1B
in cash flow from operating activities
~$5B
Reduced debt by
~$12.6B4
Returned cash to shareholders
References
* New Product Portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets), Zeposia® (ozanimod), Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag® (relatlimab plus nivolumab), Camzyos® (mavacamten) and SotyktyuTM (deucravacitinib).
1 GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.
2 This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.
3 Portfolio achievements from 2H 2019-2022.
4 Includes $4.6 billion for dividends paid and $8.0 billion for common stock repurchases.
Annual Report 2022
There is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.
© 2024 Bristol-Myers Squibb Company